Metastatic Hormone Refractory Prostate Cancer Completed Phase 1 / 2 Trials for Dasatinib (DB01254)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

IndicationStatusPhase
DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00439270Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate CancerTreatment